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Backgrounds: It remains unclear whether a persistently high exhaled nitric oxide fraction (FeNO) in
patients with controlled asthma is associated with the progressive loss of lung function.
Methods: This was a 3-year prospective study. We examined the changes in pre- and post-bronchodilator
forced expiratory volume in 1 s (FEV1) and FeNO in 140 patients with controlled asthma. We initially
determined the FeNO cut-off point for identifying patients with a rapid decline in FEV1 (>40 mL/yr).
Next, a total of 122 patients who maintained high or non-high FeNO were selected, and the associations
between the FeNO trend and changes in FEV1 and bronchodilator response (BDR) were investigated.
Results: A FeNO level >40.3 ppb yielded 43% sensitivity and 86% speciﬁcity for identifying patients with a
rapid decline in FEV1. Patients with persistently high FeNO had higher rates of decline in FEV1
(42.7 ± 37.5 mL/yr) than patients with non-high FeNO (16.7 ± 31.5 mL/yr) (p < 0.0005). The changes in
BDR from baseline to the end of the study, in patients who had high or non-high levels of FeNO
were 0.8% and 0.1%, respectively (p < 0.01). In a multivariate analysis adjusted by age, body mass index,
asthma control, blood eosinophil numbers, and FEV1% of predicted, a FeNO level of 40 ppb was
independently associated with an accelerated decline in FEV1 (p < 0.05).
Conclusions: This study suggests that FeNO is potentially valuable tool for identifying individuals who are
at risk of a progressive loss of lung function among patients with controlled asthma.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Nitric oxide (NO), a gaseous signalingmolecule generated by NO
synthase (NOS), is enhanced by inﬂammatory stimuli.1 The exhaled
nitric oxide fraction (FeNO) has been proposed as a marker of
airway inﬂammation and a guide for anti-inﬂammatory therapy in
asthma.1e3 However, a persistently high FeNO is occasionally
observed despite steroid therapy in some patients.4,5 Excessive NO
synthesis is well documented in severe asthma6,7 and a European
multicenter study suggested that the FeNO levels of patients with
severe asthma, who are refractory to conventional treatments maydicine and Infectious Disease,
1-1-1 Minami-kogushi, Ube,
Matsunaga).
ety of Allergology.
rgology. Production and hosting by Elsenot be suppressed by corticosteroids.8 Importantly, this large study
showed that the mean FeNO levels of patients with severe asthma
are similar to those of patients with non-severe asthma.8 Also, the
analysis of data from a Severe Asthma Research Program demon-
strated that 40% of the study subjects had FeNO levels of >35 ppb
regardless of the severity of asthma.4 The grouping of asthma by
FeNO has now been proposed to provide an independent classiﬁ-
cation of the asthma severity.4
Recent evidence suggests that airway inﬂammation may play an
important role in the progression of airﬂow limitation in
asthma.9e13 Cross-sectional studies that targeted patients with
severe asthma have shown associations between persistent airﬂow
limitation and eosinophilia in blood,9 sputum,10 and bronchial tis-
sues.11 Also, some longitudinal studies reported that the baseline
sputum eosinophil numbers and FeNO could predict a decline in
forced expiratory volume in 1 s (FEV1) in asthmatic patients with
ﬁxed airﬂow limitation.12,13 To identify patients who are at risk of avier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Disposition of the study patient population.
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However, it remains unclear whether a persistently high FeNO in
patients with controlled asthma is associated with the progressive
loss of lung function.
In a 3-year prospective cohort study, we recently reported that
the annual rate of change in FEV1 among patients with well-
controlled asthma was highly variable and the rapid decliners
were more likely to have higher levels of FeNO at baseline.14 In this
subsequent analysis, we ﬁrst determined the FeNO cut-off point for
identifying patients with an accelerated decline in FEV1. Next, the
patients whomaintained high or non-high FeNOwere selected, and
the associations between the FeNO trend and changes in FEV1 and
bronchodilator response (BDR) were investigated.
Methods
Study design and patients
This was a stratiﬁed analysis of a prospective cohort study. The
study subjects were followed with Asthma Control Test (ACT),
spirometry, and FeNO every 3 month over a 3-year period. The use
of asthma controllers within 24 h before an examination was pro-
hibited for all study visits. Blood eosinophil numbers and serum
speciﬁc immunoglobulin E (IgE) for common inhaled allergens
(house dust mite, cedar, ragweed, cocksfoot, dog, and cat) were
examined. Positive speciﬁc IgE to at least one allergenwas assumed
to conﬁrm the presence of atopy. The study was approved by the
Ethics Committee of Wakayama Medical University (IRB #526) and
registered with the University Hospital Medical Information
Network (UMIN 000012105).
250 Adults with stable asthma following treatment with inhaled
corticosteroids (ICS) with or without long-acting b2-agonist,
leukotriene modiﬁer, or theophylline for more than 4 years were
recruited from the outpatient clinic of Wakayama Medical Univer-
sity Hospital. Current smokers and patients with >10 pack-year
smoking history were excluded from the study. Also, patients
with poor adherence to therapy (deﬁned as <80% adherence
calculated by dividing the number of days supplied for amedication
by the number of days between the visits) or with other pulmonary
diseases such as COPD were not included. All patients had a history
of episodic dyspnea, wheezing, and documented signiﬁcant airway
reversibility and/or airway hyperresponsiveness. The changes in
FEV1 before and 15 min after inhalation of 400 mg of salbutamol
were measured to assess BDR. Airway reversibility is regarded as
signiﬁcant when FEV1 is increased by 12% and 200 mL of the
absolute volume. Airway responsiveness to methacholine was
measured using a device (Astograph; Chest, Tokyo, Japan) that
displays respiratory resistance measured via the forced oscillation
method. Airway hyperresponsiveness was deﬁned as the cumula-
tive provocative dose of methacholine causing a 100% increase in
the baseline respiratory resistance of less than 25 mg/mL. In this
analysis, 140 patients with controlled asthma aged over 25 years
old were selected based on the GINA guidelines (twice or less/week
daytime symptoms, no nocturnal symptoms, no limitation of daily
activities, twice or less/week need for reliever, normal lung func-
tion (70% FEV1/FVC ratio and 80% FEV1% of predicted), no
exacerbation in the previous one year).1 The ﬂow diagram of the
study is shown in Figure 1. Informed written consent was obtained
from each participant.
Study assessments
The FVC and FEV1 values were measured using a dry rolling seal
spirometer. The post-bronchodilator FEV1 was selected to reﬂect
loss of lung function as in other studies following lung function inpatients with asthma.14,15 The mean annual rates of changes in
FEV1 and BDR over a 3-year period were estimated for each subject
by ﬁtting a least-square regression line. The random slope was
based on time of FEV1 assessment. In total, 3168 FEV1 measure-
ments were analyzed excluding lung function data during periods
of worsening asthma (4 weeks before and 4 weeks after the start of
a severe exacerbation, deﬁned as worsening asthma requiring at
least 3 days treatment with systemic corticosteroids or as a
hospitalization due to asthma).16 Based on themagnitude of change
in FEV1 over a 3-year period, we labeled those of less than the 25th
percentile as rapid decliners. All rapid decliners had an estimated
rate of decline in FEV1 of more than 40 mL/yr. The FeNO was
measured by an online NO analyzer (NIOX MINO; Aerocrine, Solna,
Sweden). Repeated exhalations were performed to obtain two
acceptable measurements that agreed within 10% deviation, and
the average of these two values was registered.1,17
Statistical analyses
We dichotomized the subjects into two groups based on the
FeNO levels. The receiver operating characteristic (ROC) analysis
was used to ﬁnd a cut-off value for FeNO that would identify pa-
tients with a rapid decline in FEV1. The clinical characteristics were
compared using the Chi-squared test for categorical variables, and
unpaired t-tests or ManneWhitney U tests as appropriate for
continuous variables. Chi-squared test and multivariate logistic
regression analysis were used to estimate odds ratios (ORs) with
95% conﬁdence intervals (CIs) for rapid loss of FEV1. The variables
with p values <0.20 in the univariate analysis were included in the
multivariate model. All data were expressed as mean
values ± standard deviation for continuous variables. For categor-
ical variables, the numbers of observations were given in each
category. A p value of <0.05 was considered statistically signiﬁcant.
Results
The 3-year follow-up study was completed in 128 patients
(Fig. 1). A FeNO level >40.3 ppb yielded 43% sensitivity and 86%
Table 1
Baseline characteristics of study patients subdivided by exhaled nitric oxide levels.
Characteristics Non-high FeNO
(n ¼ 95)
High FeNO
(n ¼ 27)
p value
Age (yrs) 42.4 ± 13.4 47.0 ± 14.6 0.13
Gender (female/male) 67/28 16/11 0.27
Body mass index (kg/m2) 21.8 ± 4.0 22.9 ± 4.2 0.18
Smoking status (Never/Ex), n 71/24 19/8 0.65
Atopy, n (%) 74 (77.9) 23 (85.2) 0.41
Duration of asthma (yrs) 10.3 ± 3.4 10.6 ± 3.2 0.68
Dose of inhaled corticosteroids
(mg/day)y
322 ± 116 332 ± 110 0.67
Use of long-acting b2-agonist, n (%) 45 (47.4) 13 (48.1) 0.94
Use of leukotriene modiﬁer, n (%) 10 (10.5) 5 (18.5) 0.27
Use of theophylline, n (%) 6 (6.3) 3 (11.1) 0.40
Asthma Control Test (points) 23.3 ± 1.1 22.9 ± 0.9 0.08
FVC % of predicted (%) 103.5 ± 9.3 102.9 ± 10.0 0.77
FEV1/FVC ratio (%) 82.2 ± 6.9 77.2 ± 6.1 <0.005
FEV1% of predicted (%) 97.6 ± 7.4 95.2 ± 9.0 0.22
FEV1 reversibility (%) 9.2 ± 4.1 10.0 ± 5.4 0.38
Blood eosinophil numbers (cells/mL) 173 ± 151 469 ± 241 <0.0001
Exhaled nitric oxide fraction (ppb) 20.2 ± 7.4 56.5 ± 11.2 <0.0001
Data are presented as means ± SD unless otherwise stated. p Values compared
between the groups. High FeNO deﬁned as 40 ppb, and non-high FeNO deﬁned as
<40 ppb.
y Inhaled corticosteroids, expressed as ﬂuticasone propionate equivalent.
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(AUC ¼ 0.65) (Fig. 2). We labeled those with less than 40 ppb as the
non-high FeNO group, and those with greater than 40 ppb as the
high FeNO group. During the study period, 4 subjects in the high
FeNO group and 2 subjects in the non-high FeNO group were
switched over to the other group. The subsequent analyses were
performed on 122 patients who maintained high (n ¼ 27) or non-
high (n ¼ 95) levels of FeNO throughout the study period (Fig. 1).
The baseline patient characteristics subdivided by FeNO levels
are presented in Table 1. The age, gender, BMI, smoking history, and
asthma treatment were not different between the two groups,
although the high FeNO group had lower FEV1/FVC ratio
(p < 0.005), and higher blood eosinophils and FeNO (all p < 0.0001)
at baseline. Table 2 shows the characteristics during the follow-up
period and at the end of the study. Neither the dose of ICS nor other
controller use showed any difference between the two groups. The
FeNO levels were not associated with the rates of severe exacer-
bations. At the end of the study, patients with high FeNO showed
greater impairments in their ACT scores (p < 0.01) and had lower
FEV1 and FEV1/FVC ratio (all p < 0.005). As shown in Figure 3A,
patients with persistently high FeNO had higher rates of decline in
FEV1 than patients with non-high FeNO (non-high FeNO,
16.7 ± 31.5 mL/yr; high FeNO, 42.7 ± 37.5 mL/yr; p < 0.0005).
Proportion of patients who had a rate of FEV1 decline of more than
40mL/yr, in patients who had high or non-high levels of FeNOwere
48% and 19%, respectively (p < 0.005). Patients with high FeNO had
a signiﬁcantly higher risk of a rapid decline in FEV1 compared to
those with non-high FeNO (OR, 2.73; 95% CI, 1.44e5.15; p < 0.01).
The changes in BDR from baseline to the end of the study, in pa-
tients who had high or non-high levels of FeNO were 0.8% and
0.1%, respectively (p < 0.01) (Table 2 and Fig. 3B). As shown in
Table 2 and 5 of 95 subjects (5.2%) in non-high FeNO group and 5 of
27 subjects (18.5%) in high FeNO group had FEV1/FVC ratio of <70%
at the end of the study. Patients with high FeNO had a signiﬁcantly
higher risk of a ﬁxed airway obstruction (FEV1/FVC < 70%)Fig. 2. Receiver operating characteristics (ROC) curve to estimate the FeNO cut-off
point for identifying patients with a rapid decline in FEV1 (>40 mL yr1). Data labels
represent cut-off point of FeNO (arrow), area under the curve (AUC), sensitivity, and
speciﬁcity.compared to those with non-high FeNO (OR, 4.09; 95% CI,
1.09e15.38; p < 0.05).
To identify a predictor of an accelerated decline in FEV1, asso-
ciations between the binary outcome (decline in FEV1 >40 mL/yr)
and a set of covariates at baseline were also analyzed. According to
the multivariate analysis adjusted by age, BMI, ACT score, blood
eosinophil numbers, and FEV1% of predicted, a FeNO level of
40 ppb was independently associated with an accelerated decline
in FEV1 (OR, 4.42; 95% CI, 1.34e14.66; p < 0.05) (Table 3).Table 2
Clinical characteristics of patients during the follow-up period and at the end of the
study.
Characteristics Non-high FeNO
(n ¼ 95)
High FeNO
(n ¼ 27)
p Value
Follow-up period
Use of inhaled corticosteroids (%)y 95 (100.0) 27 (100.0) 1.00
Dose of inhaled corticosteroids
(mg/day)z,x
330 ± 110 359 ± 113 0.20
Use of long-acting b2-agonist, n (%)y 45 (47.4) 15 (55.6) 0.27
Use of leukotriene modiﬁer, n (%)y 9 (9.5) 5 (18.5) 0.19
Use of theophylline, n (%)y 6 (6.3) 3 (11.1) 0.40
Number of patients with a severe
exacerbation, n (%)
19 (20.0) 8 (29.6) 0.29
At the end of the study
Asthma Control Test (points) 23.3 ± 1.7 22.3 ± 1.8 <0.01
Exhaled nitric oxide fraction (ppb) 18.0 ± 6.9 57.1 ± 15.6 <0.0001
FVC % of predicted (%) 101.7 ± 10.7 98.3 ± 9.7 0.14
FEV1/FVC ratio (%) 82.1 ± 7.3 76.4 ± 7.0 <0.005
FEV1% of predicted (%) 95.1 ± 8.7 88.7 ± 10.8 <0.005
FEV1 reversibility (%) 9.2 ± 3.8 9.2 ± 4.9 0.98
Annual rates of decline in FEV1
(mL yr1)
16.7 ± 31.5 42.7 ± 37.5 <0.0005
Number of patients with FEV1 decline
>40 mL yr1, n (%)
18 (18.9) 13 (48.2) <0.005
Number of patients with FEV1/FVC
ratio <70%, n (%)
5 (5.2%) 5 (18.5%) <0.05
Annual rates of change in FEV1
reversibility (%$yr1)z
0.03 ± 0.50 0.27 ± 0.47 <0.0005
Data are presented as means ± SD unless otherwise stated. p Values compared
between the groups.
y Usage rate of medications during the follow-up period.
z Mean values during the follow-up period.
x Inhaled corticosteroids, expressed as ﬂuticasone propionate equivalent.
Fig. 3. Mean changes in (A) post-bronchodilator FEV1 and (B) bronchodilator response
(BDR) from baseline to each time point according to the FeNO levels. High FeNO
deﬁned as 40 ppb, and non-high FeNO deﬁned as <40 ppb.
Table 3
Multivariate logistic regression analysis with annual decline in forced expiratory
volume in 1 s >40 mL as the outcome.
Baseline characteristics All asthma (n ¼ 122)
Odds ratio (95% conﬁdence
interval)
p Value
Age, yrs 1.03 (0.99e1.06) 0.12
Body mass index, kg/mm2 1.03 (0.92e1.14) 0.64
Asthma Control Test, points 1.13 (0.74e1.72) 0.58
Blood eosinophil numbers, cells/mL 1.00 (0.99e1.00) 0.68
High level of FeNO (40 ppb)y 4.42 (1.34e14.66) <0.05
FEV1% of predicted, % 1.02 (0.96e1.08) 0.56
y Independent predictor of FEV1 decline >40 mL yr1.
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In this prospective cohort study of patients with controlled
asthma at baseline, we found that a persistently high FeNO was
associated with an accelerated decline in FEV1 and reduction in
BDR over time. A FeNO >40.3 ppb yielded 43% sensitivity and 86%
speciﬁcity for identifying patients with a rapid decline in FEV1.
There was no association between decline in lung function and
other potential predicting factors, such as aging, obesity, systemic
eosinophilia, asthma control, and airﬂow limitation. This study
shows that FeNO is a speciﬁc predictor of progressive loss of lung
function in patients with well-controlled asthma.
The role of high levels of FeNO in the progression of airﬂow
limitation in asthma is still uncertain. In inﬂammatory conditions,
excessive NO derived from the inducible type of NO synthase
(iNOS) is produced as well as superoxide anion from nicotinamide
adenine dinucleotide oxidase or xanthine oxidase.18,19 In general,
NO rapidly reacts with superoxide anion to produce highly reactive
nitrogen species (RNSs) such as peroxynitrite.18,19 Excessive RNSs
cause tissue injury, lipid peroxidation, and airway inﬂamma-
tion.19e21 Nitro-oxidative stress could be one of the factorsresponsible for airway remodeling,6,7,22 which may be associated
with the development of persistent airﬂow limitation in asthma.
The patients with severe adult-onset asthma mostly have persis-
tent sputum eosinophilia and increased FeNO levels despite steroid
therapy.23 Recent evidence shows that the up-regulation of iNOS in
the airway epithelium via STAT-6 and Th2-cytokines interleukin
(IL)-4 and IL-13, produces enhanced NO concentrations in exhaled
air.24 It is known that these Th2-cytokines stimulate epithelial cells
and ﬁbroblasts to promote a proﬁbrotic response.25,26 Persistently
high FeNO have also been seen in association with elevations of
concomitant Th1 cytokines such as interferon (IFN)-g.7,27 IL-4 and
IL-13 in combination with IFN-g synergistically enhance iNOS
expression.7,27 This combination may partly explain the observa-
tion that FeNO can be elevated in patients with both severe and
non-severe asthma, and it may contribute to inducing a high degree
of nitro-oxidative stress. Recent studies suggest that the charac-
teristics associated with Th2 signatures such as blood eosinophils,
periostin, and FeNO may differ by molecular background of
asthma.28e30 The mixed Th1/Th2 characteristics in patients with
asthma, even in milder disease, may be involved in their relative
steroid unresponsiveness.30e33 The IFN-g-mediated induction of
iNOS expression is virtually steroid-resistant, as evidenced both
in vitro34 and in vivo.35 Furthermore, a recent study suggests that
osteopontin and periostin, both of which can bind to extracellular
matrix proteins, might have affected the long-standing decline of
lung function by their involvement in persistent eosinophilic
inﬂammation and airway remodeling.36
The present study also identiﬁed that a persistently high FeNO is
correlated with the decrease in BDR. A reduced BDR has been used
as a surrogate marker for airway remodeling,37,38 although there
are no prospective studies showing that the lack of BDR is evidence
of structural changes. A positive relationship was observed be-
tween BDR and volume fraction of airway smooth muscle in
endobronchial biopsies from childrenwith asthma.38 Moreover, the
BDR is impaired in steroid-resistant asthma and is associatedwith a
shift in matrix metalloprotease 9/tissue inhibitor of metal-
loproteinases 1 ratio.37
An ofﬁcial ATS clinical practice guideline indicates that the FeNO
values should be interpreted by considering asthma symptoms
when monitoring airway inﬂammation.2 If a patient is asymp-
tomatic but has a high FeNO (>50 ppb), monitoring the FeNO trend
over time is recommended.2,39,40 However, several recent studies
reported that the association of high FeNO to uncontrolled
asthma4,5 and future loss of lung function.12,13 Our study extends
these data to real-life clinical care. Speciﬁcally, in patients with
controlled asthma, a persistently high FeNO was associated with a
more rapid decline in FEV1 and decrease in airway reversibility
over time, with an optimum cut-off point of FeNO 40 ppb.
The high level of FeNO was a speciﬁc but not a sensitive marker
for predicting that patients would experience a rapid decline in
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factors other than the FeNO level are associated with the excessive
loss of lung function.41e43 Importantly, we found no statistical
interaction between the rapid decline in FEV1 and other risk factors
indicating that there is potentiation of risk by the presence of high
FeNO. However, in the absence of another prospective study
examining the relationship between the FeNO trend and the
changes in FEV1 over time, further conﬁrmation of our ﬁnding is
needed.
This study had several limitations. There are some possible ex-
planations for the persistently high FeNO. Certain variables such as
poorly inhaled drug delivery or persistent exposure to allergen
could not be completely accounted for and veriﬁed. Also, no biopsy
specimens were obtained to examine whether the changes in BDR
were correlated with structural changes in the airways. Further-
more, a highly selection of the study population was necessary to
examine the associations between the FeNO trend and changes in
lung function. Thus, it can limit the generalizability of the current
ﬁndings.
In summary, we showed that a persistently high FeNO in pa-
tients with controlled asthma is associated with the progression of
airﬂow limitation and reduction in airway reversibility over time.
FeNO is suggested to be a valuable tool for identifying individuals
who are at risk of a rapid loss of lung function among patients with
asthma. These ﬁndings warrant further study of the mechanisms of
persistent FeNO elevation including patient's molecular proﬁle.Acknowledgments
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